Alexion wins approval for rare disease drug, aims to switch patients from blockbuster Soliris

Alexion Pharmaceuticals secured approval Friday from the Food and Drug Administration for a new drug called Ultomiris that will be used to treat an ultra-rare blood disease and ultimately replace the biotech’s current blockbuster, Soliris.